Genmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer

Genmab Reports Positive Phase 3 LiGeR-HN1 Results for Petosemtamab Plus Pembrolizumab in Head and Neck Cancer Genmab A/S, a biotechnology company focused on developing innovative antibody-based medicines for serious diseases,…

Read MoreGenmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer

Strand Therapeutics Doses First Patients in Clinical Trial of STX-003, a Tumor-Selective Programmable mRNA Therapy

Strand Therapeutics Doses First Patients in Phase 1 Trial of STX-003, a Programmable mRNA Therapy for Solid Tumors Strand Therapeutics, a clinical-stage biotechnology company developing programmable messenger RNA (mRNA) medicines,…

Read MoreStrand Therapeutics Doses First Patients in Clinical Trial of STX-003, a Tumor-Selective Programmable mRNA Therapy